Last reviewed · How we verify

OLE FD Adalimumab +/- MTX — Competitive Intelligence Brief

OLE FD Adalimumab +/- MTX (OLE FD Adalimumab +/- MTX) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor. Area: Immunology.

phase 3 TNF-alpha inhibitor TNF-alpha (Tumor Necrosis Factor-alpha) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

OLE FD Adalimumab +/- MTX (OLE FD Adalimumab +/- MTX) — Abbott. Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling to reduce inflammation, with optional methotrexate co-administration to enhance efficacy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
OLE FD Adalimumab +/- MTX TARGET OLE FD Adalimumab +/- MTX Abbott phase 3 TNF-alpha inhibitor TNF-alpha (Tumor Necrosis Factor-alpha)
infliximab, etanercept, adalimumab infliximab, etanercept, adalimumab University Hospital, Strasbourg, France marketed TNF-alpha inhibitor TNF-alpha (tumor necrosis factor-alpha)
Infliximab Adalimumab y Golimumab Infliximab Adalimumab y Golimumab Fundación de Investigación Biomédica - Hospital Universitario de La Princesa marketed TNF-alpha inhibitor TNF-alpha (Tumor Necrosis Factor-alpha)
PRECISION dosing Infliximab PRECISION dosing Infliximab Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) marketed TNF-alpha inhibitor monoclonal antibody TNF-alpha (Tumor Necrosis Factor-alpha)
Adalimumab, etanercept, infliximab Adalimumab, etanercept, infliximab University of Padova marketed TNF-alpha inhibitor TNF-alpha (tumor necrosis factor-alpha)
CYCLOSPORINE VS INFLIXIMAB CYCLOSPORINE VS INFLIXIMAB Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives marketed Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab) Calcineurin (cyclosporine); TNF-alpha (infliximab)
Certolizumab Pegol (CZP) Certolizumab Pegol (CZP) UCB Pharma marketed TNF-alpha inhibitor TNF-alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor class)

  1. Abbott · 4 drugs in this class
  2. Centre for Human Drug Research, Netherlands · 2 drugs in this class
  3. Samsung Bioepis Co., Ltd. · 2 drugs in this class
  4. Alvotech Swiss AG · 2 drugs in this class
  5. UCB Pharma · 2 drugs in this class
  6. Celltrion · 2 drugs in this class
  7. AbbVie (prior sponsor, Abbott) · 2 drugs in this class
  8. Assistance Publique Hopitaux De Marseille · 1 drug in this class
  9. Asan Medical Center · 1 drug in this class
  10. Carmel Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OLE FD Adalimumab +/- MTX — Competitive Intelligence Brief. https://druglandscape.com/ci/ole-fd-adalimumab-mtx. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: